<qa>  What is the name of the study that will be taken off the study?2. If central pathology review indicates a diagnosis other than ATC, the participant may continue treatment with lenvatinib per standard of care, at the discretion of the treating investigator. Participants deemed to have another diagnosis not ATC will be taken off this study and replaced for the purpose of efficacy analyses. 